마로피턴트

용도

• As an antiemetic
• As an antiemetic
• Treatment of vomiting
• Prevention of acute vomiting
• Prevention of acute vomiting
• Treatment of acute vomiting
• Prevention of vomiting due to motion sickness
• Treatment and prevention of vomiting (including chemotherapy)
• Motion sickness

투여 방법

가능한 부작용

• Pre-travel vomiting (especially at higher motion sickness doses)
• Hypersalivation
• Pain or swelling at the subcutaneous injection site
• Diarrhea
• Anorexia
• Localized injection site reactions (cats)
• Transient pain reaction during injection (very common, especially in cats)
• Haemolysis (at very high doses in cats)

주의사항 및 금기

• Puppies less than 11 weeks old (due to risk of bone marrow hypoplasia)
• Suspected gastrointestinal obstruction
• Suspected gastrointestinal perforation
• Use for longer than 48 hours without a definitive diagnosis
• Use with caution in dogs with hepatic dysfunction as maropitant is hepatically metabolized. Use with caution in puppies less than 11 weeks old due to a higher frequency and severity of bone marrow hypoplasia. The safe use of maropitant has not been evaluated in breeding, pregnant, or lactating dogs; use only following a benefit/risk assessment.

약물 상호작용

• Highly protein-bound medications: Use with caution; maropitant is highly protein-bound (99.5%) and could theoretically compete for binding sites, though clinical significance is undetermined.
• Calcium-channel antagonists: Maropitant has an affinity for calcium-channels; concurrent use should be avoided.
• Highly protein-bound drugs: Maropitant is highly bound to plasma proteins and may compete with other highly bound drugs, potentially altering free drug concentrations.

자주 묻는 질문